About BioVentrix

A singular focus on less invasive heart failure treatments

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.

BioVentrix offers benefits to all stakeholders in the heart failure:

  • Patient – improved survival and QOL by treating the underlying cause of HF less invasively
  • Payor – reduced hospitalizations and avoidance of more expensive, highly invasive procedures like transplant and LVAD
  • Provider – become a pioneer in heart failure and offer unique solutions to your patients, in the growing and most expensive disease state in the world

Improving the quality of life for heart failure patients

BioVentrix provides physicians with innovative technology that corrects the anatomical damage created by CHF to slow the progression of this debilitating and fatal disease (see figure)

The Revivent-TC™ Transcatheter Ventricular Enhancement System, improves cardiac function by restoring the shape, volume and resulting performance of the left ventricle (LV) in ischemic heart failure patients. Further, unlike the predicate operation, this technique obviates the need for cardiopulmonary bypass or placing incisions directly into the healthy myocardium. These results are achieved through a novel procedure known as Less Invasive Ventricular Enhancement™ (LIVE™). LIVE therapy excludes the scarred, nonviable portion of the LV to improve cardiac efficiency in the CHF patient, thus enhancing quality of life and functional status.

Promising, durable clinical results

Revivent TC™ System clinical results demonstrate improvements in hearts size, blood flow, level of activity, and quality of daily life (ex. health & happiness).

Clinical trials have demonstrated that once LV volume is reduced a cascade of positive c clinical outcomes follows almost immediately. Durable, significant improvements across five clinically validated outcome measures lasting beyond one-year follow-up were reported. And importantly, the Revivent TC™ System can reduce the costly re-hospitalizations associated with HF that over 50% of patients will experience within the first six months of their diagnosis.1

For detailed clinical data, click here

1Aghababian, RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. Rev Cardiovasc Med. 202;3(Supple 4): S3-9.